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Abstract
Introduction: Botswana’s AIDS response included free antiretroviral treatment (ART) since 2002, achieving 80% coverage of
persons with CD4,350 cells/ml by 2009–10. We explored impact on mortality and HIV prevalence, analyzing surveillance
and civil registration data.
Methods: Hospital natural cause admissions and deaths from the Health Statistics Unit (HSU) over 1990–2009, all-cause
deaths from Midnight Bed Census (MNC) over 1990–2011, institutional and non-institutional deaths recorded in the Registry
of Birth and Deaths (RBD) over 2003–2010, and antenatal sentinel surveillance (ANC) over 1992–2011 were compared to
numbers of persons receiving ART. Mortality was adjusted for differential coverage and completeness of institutional and
non-institutional deaths, and compared to WHO and UNAIDS Spectrum projections.
Results: HSU deaths per 1000 admissions declined 49% in adults 15–64 years over 2003–2009. RBD mortality declined 44%
(807 to 452/100,000 population in adults 15–64 years) over 2003–2010, similarly in males and females. Generally, death rates
were higher in males; declines were greater and earlier in younger adults, and in females. In contrast, death rates in adults
65+, particularly females increased over 2003–2006. MNC all-age post-neonatal mortality declined 46% and 63% in primary
and secondary level hospitals, over 2003–2011. We estimated RBD captured 80% of adult deaths over 2006–2011.
Comparing empirical, completeness-adjusted deaths to Spectrum estimates, declines over 2003–2009 were similar overall
(47% vs. 54%); however, Spectrum projected larger and earlier declines particularly in women. Following stabilization and
modest decreases over 1998–2002, HIV prevalence in pregnant women 15–24 and 25–29-years declined by .50% and
.30% through 2011, while continuing to increase in older women.
Conclusions: Adult mortality in Botswana fell markedly as ART coverage increased. HIV prevalence declines may reflect ART-
associated reductions in sexual transmission. Triangulation of surveillance system data offers a reasonable approach to
evaluate impact of HIV/AIDS interventions, complementing cohort approaches that monitor individual-level health
outcomes.
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Introduction
The dramatic increase in coverage of antiretroviral treatment
(ART) among people living with advanced HIV infection in sub-
Saharan Africa has been one of the remarkable public health
achievements in the last decade [1]. By 2012, 9.7 million people in
sub-Saharan Africa were estimated to be on ART, up from less
than 50,000 in 2003 [2]. Local epidemiological and clinical studies
in Africa have shown marked effects of ART on survival of people
living with HIV, and a variety of studies ranging from community
death and burial registers to demographic surveys, have demon-
strated community-level impact of ART in reducing mortality [3–
10]. Scientific evidence from observational, observational, ecolog-
ical and randomized control trials suggests that ART also reduces
the risk of HIV transmission during sex and a recent study in
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South Africa demonstrated that increases in community ART
coverage levels are strongly associated with decreased individual
risk [9]. Evidence of sustained countrywide population impact of
ART is limited to HIV model projections [11,12]. This is partly
because most countries in sub-Saharan Africa do not have reliable
birth and death registration systems with causes of death recording
or hospital mortality surveillance systems [13]. South Africa is an
exception, where adult mortality trends showed increases over
time coinciding with HIV epidemic spread, and recent mortality
declines that may be related to antiretroviral treatment [14].
Botswana has one of the most severe AIDS epidemics in the
world. HIV prevalence rates among women attending antenatal
clinics reached a peak of over 40% in 2003 [15]. A national
household survey with HIV testing in 2004 reported adult HIV
prevalence rates of 19.7% in males and 27.9% in females [16].
Modeling scenarios suggest over 190,000 cumulative AIDS deaths
from 1996–2012, making AIDS the leading cause of death in
adults [17].
In late 2002, the Ministry of Health initiated the ART program,
which aimed to make ART freely available to eligible individuals.
According to the national ART registry, the number of people
currently on ART increased from 10,723 in 2003 to 50,044 in
2005, and 191,940 in 2012 [18]. An estimated 66% and 96% of
individuals with CD4 cells below 200/mL were on ART by 2005
and 2009–2010, respectively (and 42% and 80% of those with
CD4 cells below 350/mL) [19]. At such levels of population
coverage of ART, the impact on adult mortality and morbidity
would be expected to be measurable, particularly given the rapid
increases in mortality and HIV/AIDS-related illness in these
groups during the 1990s.
This study aimed to document the population impact of HIV/
AIDS and ART on adult mortality over the course of the epidemic
by analyzing two independent hospital-based morbidity and
mortality surveillance systems, the civil death registry and
antenatal HIV sentinel surveillance.
Materials and Methods
Botswana has three parallel public health surveillance systems,
and an ART treatment registry, that together provide data to
explore temporal changes in HIV-related morbidity and mortality
at the population level. We analyzed two surveillance systems that
record hospital deaths and admissions through different, indepen-
dent processes; a nascent civil registration system that indepen-
dently records deaths in institutional settings (i.e. in health facilities)
as well as deaths from non-institutional settings (i.e. outside health
facilities), over 2003–2010; the Botswana antiretroviral treatment
registry over 2003–2010, and HIV prevalence data from antenatal
HIV surveillance over 1992–2011. Key variables, summary data
and subcategories of each variable that were used for analysis, are
described in Table 1.
Ethics
RBD data were accessed with an Institutional Review Board
permit issued to an author (ML) from the Botswana Ministry of
Health’s Health Research Unit. HSU and MNC data were in the
form of annual Health Statistics Reports for the period 1990–2011
and were provided by the Botswana Ministry of Health; they are in
the public domain. Health Statistics Reports for the period 1990–
2007 used in this investigation are archived in the WHO library in
Geneva, Switzerland. The antiretroviral registry data was provid-
ed by the MASA program, Ministry of Health Botswana, for which
no permit was required.
Data Sources
Health Statistics Unit morbidity and mortality
reports. Morbidity and mortality recorded in institutions are
reported monthly by district health teams to the Ministry of
Health’s Health Statistics Unit (HSU), using reporting form MoH
017 since 2003 (and a similar form in earlier years) in most cases,
and in fewer cases directly from hospitals to HSU using an
electronic system known as the Integrated Patient Management
System. Individual records of discharges (alive or dead) contain
demographic, diagnostic and discharge information, and personal
identification. Non-institutional deaths are investigated by district
welfare officers, reported to village chiefs, and then reported to the
HSU using reporting form MoH 3002 (from 2003, and a similar
form in earlier years). HSU reports the data to the Central
Statistical Office. The HSU codes each discharge or death
according to the WHO International Classification of Diseases
(ICD, 9th or 10th revision). All information from Morbidity,
Mortality and Obstetric In-patient forms, including cause of death,
is entered into a computerized database, which has been
maintained by the HSU and the CSO since the early 1990s.
The accuracy of HSU data (inpatient admission and deaths) is
checked annually at the facility level for missing variables such as
age, sex and diagnosis and timely reporting.
From these we analyzed nationally aggregated data on hospital
admissions and discharges due to death by age, sex, and cause of
death according to ICD-9 for years 1990–2003 and ICD-10 for
years 2004–2009. The Statistical Report for 1993 was misplaced;
therefore missing data for 1993 was imputed using simple
interpolation between 1992 and 1994 data points. Age was not
specified in 2% of admissions and 3% of deaths and these were
imputed by redistribution of cases based on proportionate age
distribution. We focused the analysis on 160,769 deaths reported
in adults aged $15 years, of which 18,583 (12%) occurred in non-
institutional settings. In order to better capture the effect of HIV-
related mortality in institutional settings, we further restricted our
analysis by removing data attributed to injuries (N=4,471 deaths
and N=221,807 admissions, 63% of which were male); and
deaths separately categorized as external being largely from
injuries, poisoning or other adverse events with additional
information regarding environmental circumstances of death
(N= 3,307, 67% of which were male). These well-defined causes
are unlikely to include any mis-classified HIV-related deaths,
whereas the remaining natural causes of deaths, notably Pneu-
monia, Stroke, Undetermined cause, and Other causes, are known
from earlier investigations in Botswana to often represent
misattribution of HIV-related deaths – since HIV-deaths are
rarely coded as HIV/AIDS.
Hospital midnight census. Independent of the HSU
morbidity and mortality surveillance system, hospital admissions
and deaths among persons aged .28 days are monitored through
a daily hospital midnight bed census (MNC). These data include
hospital admissions, discharge status (including deaths), and
numbers of occupied beds, but without patient age, sex or causes
of death. Completeness of MNC reporting is monitored with
active follow-up on a monthly basis.
From annual reports published by the Central Statistical Office
and unpublished reports from the Ministry of Health, we extracted
numbers of admissions and discharges (live or dead) by facility for
years 1990–2011. Data were summarized by year and presented
from hospitals at three service levels: (1) 17 primary hospitals with
a total bed capacity of 752 and 30,262 annual admissions in 2006;
(2) 18 general or secondary level hospitals with a total bed capacity
of 2,729 and 127, 920 annual admissions in 2006, which included
(3) Botswana’s two main referral hospitals, Princess Marina in
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Gaborone, the capital city of Botswana, and Nyangabwe in
Francistown.
Registry of Births and Deaths. The Registry of Births and
Deaths (RBD), located within the Department of Civil and
National Registration in the Ministry of Labour and Home Affairs,
also independently tracks and aggregates information on deaths
from institutional settings, and complements these with a (near-
equally large number of) death reports from non-institutional
settings. Reporting of deaths is legally mandated and to be
provided by medical practitioners or other persons who most
recently attended the deceased. Information on decedents in
health institutions includes demographic data, enumeration of
symptoms at the time of death, duration of illness and
hospitalization, and causes of death as certified by the medical
officer of the institution in which the death occurred. If a death
occurred in a non-institutional setting, only demographic data is
collected and the death is then certified by the village or town
chief. The completed forms (CRD-2 for institutional deaths and
CRD-1 for non-institutional deaths) are sent to the RBD in
Gaborone, where the information is processed into a death
certificate and entered into a computerized database. A cross-
sectional analysis of this registry has been published elsewhere
[20].
We examined RBD-recorded mortality over the period 2003–
2010 (N= 98,614, all ages combined) by age, year, setting
(institutional vs. non-institutional), and district to assess reporting
consistency. Data were excluded for deaths with missing age
(N= 41) and from two of 41 districts (N= 4002), in which visual
observations of trends indicated inconsistent reporting over the
time period from 2003–2009. Non-institutional settings accounted
for 40% of RBD deaths in adults and 25% of those in children
from 2003 to 2010.
ART treatment registry and HIV antenatal sentinel
surveillance. The Botswana Ministry of Health ART program
(MASA, a Setswana word that means ‘‘new dawn’’) maintains a
treatment registry that provides information on persons who have
ever and who are currently receiving ART by district of residence,
sex, age group (,15 or $15 years of age), CD4 cells/mL on
initiation of ART, and vital status. The program has an active
follow-up system to assess patient adherence and vital status [18].
From the treatment registry, we analyzed the number of persons
alive on ART by sex ages $15 years for the period 2003–2010.
The Ministry of Health, Botswana Ministry of Health has
conducted HIV sentinel surveillance for monitoring the HIV
epidemic among 15–49 year old pregnant women since 1992
according to international guidelines. Surveys have occurred on an
annual basis except for the years 2004, 2008, and 2010. A detailed
report summarizing the findings in 2011 and retrospective data to
1992 has been reported by the Department of HIV and AIDS
Prevention Botswana [15].
Mortality projections by Spectrum estimation model and
WHO lifetables. The Spectrum HIV policy model was
developed and used by UNAIDS to estimate and project HIV-
related mortality burden and treatment needs in countries with
generalized HIV epidemics [12]. WHO with international health
partners constructs life tables summarizing national populations’
all-cause mortality patterns by age and sex, based on data reported
through national civil registration systems, censuses and household
surveys adjusted in a standardized for data completeness, coverage
and quality [21]. We used Spectrum projections over the period
2003–2010, conducted and agreed between Botswana’s NAC and
UNAIDS in August 2011, and WHO life table estimates for
Botswana’s national population as of 2009, for comparing all-
cause adult mortality against the empirical data sources.
Analytic Plan
Because of the often poor recording of the cause of death on
death certificates (with a stable 50% of causes on death certificates
ill-defined) and notably underreporting of HIV deaths to allay
perceived stigma, we chose to rely on the analysis of trends in
mortality or morbidity from natural causes, where such disaggre-
gation was possible, in the age groups most affected by HIV rather
than those coded as HIV-related [22,23]. From HSU data, we
analyzed annual hospital admission rates per 1000 population and
hospital death rates per 1000 admissions (calculated as live
discharges plus deaths), and hospital deaths per 100,000 popula-
tion, each by gender and age group (among adults 15 years and
above) over 1990–2009, excluding admissions and deaths from
non-natural causes. From MNC data, case fatality ratios (for all
ages.28 days combined) were calculated using all-cause deaths as
the numerator and all-cause live discharges plus deaths as the
Table 1. Variables used for the analysis by information source.
Information Source Original Data Format Years Covered Variables Obtained and Analyzed Dis-aggregations Analyzed
Register of Births
and Deaths (RBD)
Unpublished PDF printouts
from death certificate
database
2003–2010 Deaths all ages: N = 98,614;
Deaths $15 years: N = 85,455.
Age, sex, setting (institutional and
non-institutional), year and cause
of death (natural and non-natural).
Health Statistics Health Statistics Reports 1990–2009 Deaths all ages: N = 165,975; Admissions
all ages: N = 1,996,355; Natural-cause
deaths, $15 years: N = 106,189; Natural-
cause admissions, $15 years: N = 1,345,302.
Age, sex, setting, year of admission
and death; cause of death and
admission (ICD-9 or ICD-10 codes).
Hospital midnight
census
Health Statistics Report
for years 1990–2009;
unpublished digital reports
for years 2010–2011
1990–2011 Admissions and deaths $age 28 days
from all causes. Admissions:
N = 2,804,291; Deaths: N = 147,312.
Year of admission; year of death
and facility type.
ART Treatment
Registry (MASA)
Excel data base provided
by MASA program
2002–2010 Patients ever and currently on ART.
All ages: N = 165,654 and
N= 123,474, respectively.
Age groups ,15 versus $15 years.
Cumulative by year.
Antenatal HIV
Sentinel surveillance
Published technical report 1992–2003 (all years),
2005–2007 (3 years),
2009 and 2011
HIV prevalence among pregnant
women attending antenatal
care for the first time.
Age groups: 15–19; 20–24;25–
29;30–34;35–39;40–49 years;
calendar year and site.
doi:10.1371/journal.pone.0100431.t001
Impact of Antiretrovirals on Mortality in Botswana
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e100431
Impact of Antiretrovirals on Mortality in Botswana
PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e100431
denominator. The RBD data were analyzed by age, sex, and
setting (within medical institution versus outside of medical
institution) for all causes and causes excluding injuries or external
causes for the period 2003–2010. Corresponding hospitalizations
and deaths rates were also calculated using UN Botswana
population estimates [24]. We then compared temporal trends
in mortality from the three mortality surveillance systems, and in
HIV prevalence by age in pregnant women attending antenatal
clinics with trends in persons receiving antiretroviral drugs, to
determine temporal associations between reductions in deaths or
HIV prevalence and increasing antiretroviral coverage.
Estimates of the number of deaths in Botswana during the
course of the AIDS epidemic have varied widely [25]. According
to the Botswana Central Statistics Office’s Government Statisti-
cian, the accuracy of the HSU institutional death reporting when
compared to population census data was estimated to be over 95%
in 2001 [26]; however, WHO life table estimates that RBD data
both institutional and non-institutional captured only 67% of
deaths in 2003, improving to around 80% capture over 2006–
2010 [21,25]. The difference is believed to relate to underreport-
ing of deaths in non-institutional settings [25]. While institutional
reporting appears to have improved over time, the reported
number of non-institutional deaths has remained constant. The
proportion of HSU non-institutional deaths thus fell from 15.1%
in 2005 to 4.3% in 2005 in ages 15–64 and 4.7% to 1.9% in ages
65+, remaining at the lower levels through 2009. During the same
time period, however, 40% of RBD deaths in adults were reported
as non-institutional and that proportion varied little over time.
We therefore estimated, and adjusted for, completeness of death
registration in adults from 2003–2010 using the following
approach. We combined institutional adult deaths (ages 15 years
and older) from Health Statistics (HSU) and non-institutional adult
deaths (ages 15 years and older) from the RBD, assuming that
HSU best captures institutional deaths but largely fails to capture
non-institutional deaths. We then examined the observed patterns
of mortality by year from 2003–2010 in ages 65+ by sex as
indicative of possible changes in reporting accuracy, since at these
ages the contribution of HIV mortality is reported to be small [27].
We compared both unadjusted and completeness-adjusted empir-
ical observed mortality trends, with trends in WHO mortality
estimates and in projections of the Spectrum model.
Results
The HSU analyses yielded a total of 106,189 hospital deaths in
adults $15 years of age, of which there were 58,941 deaths among
497,564 admissions in males, and 47,248 deaths among 847,756
admissions in females over 1990–2009, The daily MNC enumer-
ated 147,312 deaths among 2,804,291 hospital admissions of all
ages excluding neonates over 1990–2011, and the RBD enumer-
ated 98,614 deaths (of which N=85,455, or 87%, were in $15
years) over 2003–2010.
Health Statistics Unit: all-cause natural hospital
admissions and deaths, 1990–2009
From 1992 to 2004, HSU-recorded hospital admissions and
deaths in ages 15–64 increased six- and three-fold, respectively, for
males and seven- and four-fold in females (Figure 1A). From 2004
to 2007 deaths stabilized, and then declined sharply starting in
2008. Admission trends generally mirror trends in deaths through
2006, after which male admissions stabilized while female
admissions continued to increase. From 2003 to 2009, hospital
death rates declined by 49% (103 to 52 deaths/1000 admissions)
in adults 15–64; by 55% in females (75 to 34 deaths/1000
admissions) and by 38% in males (153 to 96 deaths/1000
admissions (Figure 1B).
Among adults, the increase in hospital admissions and deaths
beginning in 1992 was most marked in adults 25–44 years, the
group with highest HIV prevalence (Figure 1 C–D). Admissions
stabilized in 2000 in males ages 25–44 years and later in older
males except in ages 65+ years, where they continued to increase.
In contrast, female admissions continued to increase through
2009. This phenomenon is particularly evident in ages 25–44
years, from 2006 onwards, and relates to an increase in admissions
attributed to obstetrical complications. Deaths and hospital death
rates (deaths/1000 admissions) peaked and began to decline over
2004–2007; however, the magnitude and timing of declines varied
and was generally greater in females and occurring later in older
age groups (Figure 1 F–H). Percentage declines in death rates from
2004–2009 by age group and sex were as follows: ages 15–24, 43%
in males and 68% in females; ages 25–44, 42% in males and 63%
in females; ages 45–64, 30% in males and 45% in females; and
ages 65+, 14% in males and 18% in females. Death rates in males
were higher than in females across time in all age groups, except in
15–24 year-olds. Similar patterns are evident when hospital deaths
were expressed using population sizes as the denominator, instead
of admissions.
Midnight Census: Hospital admissions and deaths, 1990–
2011
MNC trends show similar patterns, with increasing all-cause
post-neonatal hospital admissions and deaths from the early 1990s.
The subsequent stabilization in admissions and decline in deaths
after 2004 is most evident in primary hospitals and referral
hospitals (Figure 2 A–B). In-patient mortality rates increased
linearly from 1990 to a peak in 2003–4; after which they declined
by over half, between 2003 and 2010, falling by 63% and 46% in
general and primary hospitals, respectively (Figure 2 C).
Registry of Births and Deaths: Institutional and non-
Institutional deaths, 2003–2010
A total of 85,455 adult (age 15+years) deaths were reported by
the RBD over 2003–2010: 52% and 48% were in males and
females, respectively; and 60% and 40% occurred in institutional
and non-institutional settings. The distribution of deaths by sex
and setting remained relatively constant over the period. All-cause
mortality rates in 15–64-year-olds, as well deaths with known
injury causes excluded, declined by 44% and 46%, respectively
over 2003–2010, and similarly in males and females (Figure 3A).
Institutional and non-institutional deaths declined 38% and 52%,
respectively. Declines were earlier and greater in ages 25–44
compared to ages 45–64, and were similar by setting and exclusion
of injury related causes (Figure 3B; Figure S1). In contrast, death
rates increased over 2003–2010 for adults 65+ years, by 35% for
females and by 13% for males and particularly over 2003–7
(Figure 3B), without difference between institutional and non-
institutional deaths (Figure S1). The average male-to-female ratio
Figure 1. Trends in HSU-recorded hospital admissions and deaths in adults 15–64 years, 1990–2009. (A) Hospital admissions and deaths
by sex; (B) Hospital deaths/1000 admissions (C) Age-specific hospital admissions, males; (D) Age-specific hospital admissions, females; (E & F) Age-
specific hospital deaths, males and females; (G & H) Age- specific hospital case fatality rates, males and females.
doi:10.1371/journal.pone.0100431.g001
Impact of Antiretrovirals on Mortality in Botswana
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e100431
in death rates for RBD data overall and with injury causes
excluded were 111 males/100 females and 105 males/100
females, respectively, for ages 15–64; however when stratified by
age (at a priori chosen cut-off of 35 years), ratios in ages 35–64 years
were over twice those of younger adults (Figure 3C).
Temporal Association of trends in mortality, antiretroviral
use and HIV prevalence from antenatal HIV surveillance
Trends in reported deaths from the three public surveillance
systems and numbers of persons receiving ART over 1990–2011
are summarized in Figure 4A. Mortality crested in 2003–2004 and
declined considerably through 2009–2011: all-cause MNC deaths
in ages .28 days declined 34% from 2003 (N= 9,923) to
2011(N= 6,537); all-cause RBD deaths in ages 15–64 declined
36% (from N=8,940 in 2003 to 5,757 in 2010); all natural cause
HSU institutional deaths declined 43% (from 7,712 in 2004 to
4,414 in 2009).
In comparison, trends in HIV prevalence from antenatal
sentinel surveillance sites over 1992–2011 (Figure 4B) among
15–29 year olds illustrate a gradual epidemic reversal, from
epidemic spread through stabilization into decline, which persisted
and accelerated after start of ART scale-up. In the age groups with
highest incidence of new infections, prevalence declines started in
the late 1990s for 15–24 year-old women and around 2000–2003
for women 25–29 years 2 and these declines persisted after 2003
(fitted, for all 3 groups, by quadratic models, with calendar year
having both a significant linear positive as well as a quadratic
negative effect, R2.0.70, with p,0.01 for the quadratic term in
all 3 groups).
In contrast, for women above 30 years – in whom prevalence
trends mainly reflect survival after earlier HIV infection, rather
than new infections – prevalence continued to rise throughout the
2000s (fitted by linear time trends throughout 1992–2011, at R2.
0.77, p,0.002 for all 3 groups – without any strong quadratic
effects).
Completeness of mortality capture and comparisons to
modeled mortality trends
Comparison to WHO life table estimates suggests that
completeness of death reporting in the RBD for ages $65 years
increased somewhat over the time period evaluated, at 66% in
2003–04, 74% in 2005, and between 79% and 82% over 2006–
2010. Assuming that completeness in reporting had improved
similarly over time for younger adults, RBD records would thus
underestimate the mortality declines over 2004–2010. However, a
substantial difference between rate increases in females ages $65
years compared to those of males, raised concerns that some of the
observed death rates in ages $65 years, particularly evident from
2003–2006, may be confounded by limited access to care or other
disease-related factors in addition to improved reporting. Given
this concern we applied a conservative annual adjustment factor
for underreporting over the period 2003–2006, based on the
average WHO-estimated reporting completeness ages 15–64. This
adjustment factor changed the assumed reporting capture in adults
from an average of 60% from 2003–2005 to 87% by 2009.
Figure 2. Mid-Night Census data from primary and general
service category hospitals and referral hospitals (Princess
Marina in Gaborone, and Nyangabwe in Francistown), 1990–
2011. (A) All cause inpatient admissions excluding neonates; (B)
Inpatient deaths; (C) Inpatient mortality ratio (deaths per 100
admissions).
doi:10.1371/journal.pone.0100431.g002
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After adjusting trends in mortality rates for lower capture of
non–institutional deaths and potential underreporting, mortality
declines from 2003 to 2009 changed from an unadjusted 33% and
47% in RBD and HSU data, to 47% in the empirical adjusted
estimate (HSU and RBD). This adjusted decline was still slightly
less than declines estimated by the WHO life table (55%) and the
Spectrum projection model (54%) over the same period (Figure 5
A). Both modeling methods estimated slightly larger declines in
women than in men, but these differences reduced in the late-
2000s. Among the three sources, Spectrum estimated the largest
cumulative number of all-cause deaths.
The scale of death rate declines in ages 25–34 years is similar
across the three sources. However, Spectrum estimated relatively
higher death rates and numbers in both men and women, and
declines of greater magnitude and occurring earlier, particularly in
women, compared to other sources (Figure S2 A–C). The average
male-to-female death ratios from 2003–2009 for the RBD data
and Spectrum were 106 males/100 females and 95 males/100
females, respectively, for ages 15–64. Ratios in ages 35–64 were
substantially higher (33%–48%) than RBD based estimates than
those generated by Spectrum (Figure S2 D).
Discussion
The ability to evaluate impact of nation-wide disease control
programs using ecological analysis is constrained by the inevitable
lack of a no-program control group. Although this analysis of
trends across three surveillance systems cannot provide causality,
the strength and consistency of time trends across the independent
systems and the close temporal relationship of mortality declines
with intervention scale-up provide strong plausibility of the impact
of first the spread of HIV and then the HIV response, including
ART, on adult mortality trends in Botswana. Hospital morbidity
and mortality rates increased five-fold from 1990–2003 among age
groups most affected by HIV infection [28]. Co-incident with the
rollout of ART in 2003, hospital deaths stabilized and then
declined, most markedly in young adults (15–29 years) and in
females. Hospital mortality declines were corroborated by an
independently collected nightly bed-census system that indicated a
55% decline in hospital case fatality rates over 2003–2011.
Declines of similar magnitude were evident in civil registration
data, again most marked in young adults. The association of
increases then declines in mortality evident in age groups most
affected by HIV and the subsequent decline coinciding with ART
uptake offers is consistent with an effect of ART in prolonging
survival among persons with HIV immune-suppression. The
magnitude of mortality declines associated with ART treatment is
similar to that earlier observed in higher-income settings [29,30].
Earlier ongoing declines in HIV prevalence, related to
prevention or natural epidemic dynamics, and increased uptake
of ART have likely contributed to the mortality decline in young
adults, which was more marked than declines in older age groups.
The mortality pattern mirrors, with several years delay, trends in
HIV prevalence, which in pregnant women aged 15–24 fell by
60% over 1998–2011, and by 34% in pregnant women aged 25–
29 years from 2003, whereas HIV prevalence stabilized or
continued to increase in older pregnant women [15,16,31]. The
apparent acceleration in HIV prevalence declines in 15–29 year-
olds over 2003–2011 may relate to concurrent ART scale-up,
which should reduce viral load and sexual transmission efficiency
[9,32]. Although reductions in high risk sexual behaviors may have
contributed to reductions in HIV incidence in this age group,
evidence from population surveys suggests that that levels of risk
behaviors have not changed dramatically since 2001 [15,31].
Furthermore, the coincident drop in prevalence particularly in
ages 20–29 suggests an association with common external
exposure effect (i.e., ART effect on HIV incidence) compounding
Figure 3. Death rates per 100,000 population* in adults, by sex
and setting and male to female rate ratios, Registry of Births
and Deaths (RBD), 2003–2010. (A) RBD total, RBD excluding injuries
and external causes, institutional, and non-institutional setting, by sex,
for ages 15–64; (B) RBD death rates by age and sex; (C) Ratio of male
death rates to female death rates ages 15–34 and 35–64.
doi:10.1371/journal.pone.0100431.g003
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the ongoing natural dynamics and cohort ageing. Comparison of
age-specific HIV prevalence between Botswana’s fourth national
HIV/AIDS population survey (BAIS 2012) and similar represen-
tative household surveys conducted in earlier years will provide
important evidence to explore this hypothesis [33].
Biases related to data quality in terms of completeness and
coverage often limits analysis and interpretation of surveillance,
survey or civil registration data. The accuracy of cause of death
from these sources was of limited quality; therefore, we focused our
analyses on trends in adult mortality from all natural causes by age
and sex. The observed patterns of mortality were similar to those
reported for AIDS cases from other settings and generally similar
to projections from epidemiological models [28,30]. However
there were notable differences: magnitudes of mortality decline in
Figure 4. Trends in deaths, ART coverage rates and HIV prevalence among pregnant women. (A) Deaths reported from Health Statistics
(HSU; institutional natural-cause deaths only), Hospital Midnight Census (MNC), and Registry of Births and Deaths (RBD; institutional and non-
institutional, including non-natural causes) and estimated ART treatment coverage rates of persons $15 years with CD4 cells ,200/mL and ,350/mL,
1990–2011; (B) HIV prevalence by age group among pregnant women from the antenatal sentinel surveillance system, 1992–2011. Dashed lines
represent best fitting quadratic (left) and linear (right) curves.
doi:10.1371/journal.pone.0100431.g004
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ages 15–64 were smaller and later in the empirical data compared
to model projections, especially for older adults, and for ages 35–
64 years the surveillance systems recorded more deaths in males
than in females, whereas Spectrum projected male-to-female
mortality rate ratios below 1 (Figure S2 D). The differences
between observed and modeled mortality could relate to biases
associated with variations in reporting completeness by age, sex
and calendar year– which our adjustments to the empirical data
may not fully have solved. In addition, imprecise modeling
assumptions regarding the timing and peak in HIV incidence, or
other HIV dynamics parameters – shared between WHO life-
tables and Spectrum projections – may explain differences [34].
Spectrum projections may overestimate HIV incidence and
resulting mortality rates in younger age groups, as it assumes
relatively static age-specific HIV-incidence over time [28].
The lag in mortality decline observed in older age groups and
the persistent high mortality in males, evident in RBD and HSU,
are less likely related to data quality issues; however, they may be
plausibly explained by differential access to HIV testing, counsel-
ing and ART by age and gender. A national household survey
performed in 2008 indicated that 41% of men aged 15–64 had
never been HIV-tested, compared to only 25% of females, while in
the same year among 61,314 persons who reported accessing ART
services, 32% were male and 68% were females [31]. Indeed,
health-care seeking is lower in males than in females, as males in
general don’t access public primary health services afforded
women through reproductive health services. Other contributors
to the lesser mortality declines in men may include social, host and
lifestyle factors that place males and older adult males at higher
risk for poor health outcomes, for HIV/AIDS as well as common
chronic diseases such as diabetes, hypertension, heart disease,
stroke and renal failure [35–40].
Also the recorded increase in mortality over 2003–2006 in ages
65+, notably in females and evident in both institutional and non-
institutional settings, is difficult to attribute entirely to improving
reporting completeness, for the following reasons: HIV prevalence
was above 10% in the 65+ age group in 2003: the proportion of
HIV-attributed reported deaths (albeit largely undercounted) in
these ages more than doubled between 2003 and 2010, while
deaths from other causes remained stable, and HIV deaths in
younger ages declined. High risk for HIV infection and increasing
mortality in ages 65+ has been reported in Kenya, and poorer
clinical outcomes for older people on ART have also been
reported elsewhere [41]. The temporal relationship of this finding
to early ART roll-out and its predominance in females may relate
to treatment complications such as the ART metabolic syndrome,
risk factors of which include older age and obesity, the latter being
more common in Batswana females than males [42,43].
All in all, reporting biases are unlikely the predominant
explanation for the mortality shifts observed in Botswana’s
national surveillance systems, given the similarity of initial rises
and subsequent declines across the three independent monitoring
systems, and their consistency with morbidity and mortality age
patterns and trends typical of AIDS [28,44–46], and the close
temporal association of onset of declines with the roll-out of ART.
The triangulation approach demonstrates the value of evaluat-
ing program impact from basic epidemiological and ecological
analysis of multiple health surveillance data, even those considered
of imperfect quality, noting that limitations frequently associated
with observational data (i.e. the ecologic fallacy) may often be
overstated [48]. According to WHO life-table estimates, the RBD
civil registration captured no less than 80% of estimated adult
deaths over 2006–2010, and possibly more given uncertainties in
the demographic modeling approaches. Triangulation among
several routine data sources can provide a critical basis to evaluate
the impact of evolving disease trends including HIV/AIDS and to
highlight emerging risks that may not be identified by periodic
surveys, one-off small-scale studies or epidemiological modeling.
As biomedical interventions assume an increasingly dominant role
in HIV/AIDS control, refining surveillance systems that report
hospital HIV-related morbidity and mortality by ART treatment
status and improving their timely reporting would be an important
adjunct to current ART impact evaluation systems (i.e. based on
ART treatment registries, program output data and epidemiolog-
ical simulation modeling). AIDS surveillance systems served as the
foundation for monitoring AIDS and HIV impact in the past and
could be useful again in identifying differential coverage and
impact of interventions across populations and geographic areas,
providing more direct empirical evidence of program impact than
modeling approaches. Furthermore, examination of hospital-level
surveillance data can provide insight to potential differential
disease trends (HIV and non-HIV) by time, age or gender,
informing emerging health risks or inequalities in care that can
better guide health policy and research. Improved mortality
estimates will stem from formal validation of the Botswana
mortality reporting systems, including comparisons with mortality
patterns with neighboring South Africa, which had similar HIV
dynamics but a high capture rates of adult mortality over the past
two decades [47], as well as with mortality statistics data from
Botswana’s 2011 population census [48].
Our findings and methodological approach may not be
generalizable to other countries in sub-Saharan Africa. Botswana
benefits from the highest socioeconomic status in sub-Saharan
Africa, a superior health care infrastructure and an aggressive
early response to provide ART to nearly everyone eligible under
WHO recommendations. [18]. Few countries in sub-Saharan
Africa have functional vital registration or Health Management
Information Systems like Botswana’s; and only South Africa has a
vital registration that meets international quality standards.
Nevertheless, countries are improving their systems and many
countries now have some system of morbidity and mortality
Figure 5. Comparison of trends in all-cause death rates per
100,000 population in ages 15–64 by sex and total, between
Spectrum epidemiological projection model, WHO life-tables,
and empirical surveillance data (RBD+HSU combined) with and
without adjustments for estimated reporting completeness.
doi:10.1371/journal.pone.0100431.g005
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monitoring that may be useful for managing and evaluating health
events and interventions [49].
In summary, our findings indicate that the benefits of ART in
reducing adult deaths in Botswana may be of similar scale to that
in more developed countries. The co-incident accelerated decline
in HIV prevalence in pregnant women may reflect an ART-
related reduction in HIV incidence at the population level. The
magnitude of mortality reduction corroborates empirical evidence
to confirm progress in achieving The United Nations 2015
Millennium Development Goal 6 of reducing AIDS deaths by
2015, and to set reasonable targets there beyond [50].
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